CCNE1 and BRD4 expression and platinum resistance in high-grade serous ovarian cancers

被引：0
|
作者：
Petersen, S. S. [1 ]
Wilson, A. J. [2 ]
Khabele, D. [1 ]
机构：
[1] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2437
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [31] Investigating NKAPL, a potential marker for platinum resistance, in high-grade serous ovarian cancer
    Schafer, Lea
    Silva, Romina
    Stewart, Gavin
    O'Toole, Sharon
    Perry, Antoinette
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A92 - A93
  • [32] Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
    Huan Wu
    Rongrong Li
    Zhiwei Zhang
    Huiyang Jiang
    Hanlin Ma
    Cunzhong Yuan
    Chenggong Sun
    Yingwei Li
    Beihua Kong
    Journal of Ovarian Research, 12
  • [33] Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance
    Kido, Kansuke
    Nojima, Satoshi
    Motooka, Daisuke
    Nomura, Yusuke
    Kohara, Masaharu
    Sato, Kazuaki
    Ohshima, Kenji
    Tahara, Shinichiro
    Kurashige, Masako
    Umeda, Daisuke
    Takashima, Tsuyoshi
    Kiyokawa, Hiroki
    Ukon, Koto
    Matsui, Takahiro
    Okuzaki, Daisuke
    Morii, Eiichi
    JOURNAL OF PATHOLOGY, 2023, 260 (01): : 56 - 70
  • [34] Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
    Azzalini, Eros
    Stanta, Giorgio
    Canzonieri, Vincenzo
    Bonin, Serena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [35] PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification
    Zhang, Xiaoming
    Wang, Aihui
    Han, Lucy
    Liang, Brooke
    Allard, Grace
    Diver, Elisabeth
    Howitt, Brooke E.
    MODERN PATHOLOGY, 2023, 36 (05)
  • [36] URI1, BRCA1/BRCA2 and CCNE1 as potential drivers of a poor: Prognosis subset of High-grade Serous Ovarian Cancer (HGSOC)
    Aziz, D.
    Etemadmoghadam, D.
    Yeung, G. Au
    Muranyi, A.
    Gresshoff, I.
    Christie, M.
    Tubbs, A.
    Shanmugam, K.
    Boyden, D.
    Waring, P.
    VIRCHOWS ARCHIV, 2016, 469 : S20 - S21
  • [37] The novel oral Chk1 inhibitor, SRA737, is active in both PARP inhibitor resistant and CCNE1 amplified high grade serous ovarian cancers
    Xu, Haineng
    Medvedev, Sergey
    Pandya, Ashka
    Kim, Hyoung
    Kinose, Yasuto
    Brown, Eric
    Hansen, Ryan J.
    Strouse, Bryan
    Milutinovic, Snezana
    Hassig, Christian
    Simpkins, Fiona
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma
    Cohen, Samantha
    Mosig, Rebecca
    Moshier, Erin
    Pereira, Elena
    Rahaman, Jamal
    Prasad-Hayes, Monica
    Halpert, Richard
    Billaud, Jean-Noel
    Dottino, Peter
    Martignetti, John A.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (03) : 591 - 598
  • [39] Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer
    Silva, Romina
    Glennon, Kate
    Metoudi, Michael
    Moran, Bruce
    Salta, Sofia
    Slattery, Karen
    Treacy, Ann
    Martin, Terri
    Shaw, Jacqui
    Doran, Peter
    Lynch, Lydia
    Jeronimo, Carmen
    Perry, Antoinette S.
    Brennan, Donal J.
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 120 - 132
  • [40] Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
    Huan Wu
    Rongrong Li
    Zhiwei Zhang
    Huiyang Jiang
    Hanlin Ma
    Cunzhong Yuan
    Chenggong Sun
    Yingwei Li
    Beihua Kong
    Journal of Ovarian Research, 13
12345